Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
On Other Exchanges
Symbol
Exchange
undefined is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

valeritas inc () Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALERITAS INC ()

Related News

No related news articles were found.

valeritas inc () Related Businessweek News

No Related Businessweek News Found

valeritas inc () Details

Valeritas, Inc., a medical technology company, develops and sells technologies and solutions for the treatment of patients with Type 2 diabetes. It offers V-Go, a disposable insulin delivery device for basal-bolus therapy. The company’s development portfolio also includes h-Patch, a controlled delivery technology platform; Mini-Ject, a disposable needle-free injection system that delivers drugs ranging from small molecules to large proteins, antibodies, and vaccines; and Micro-Trans microneedle array patch technology to deliver drugs into the dermis layer of the skin. Valeritas, Inc. sells V-Go to third-party wholesalers and medical supply distributors in the United States. The company was founded in 2006 and is based in Bridgewater, New Jersey.

121 Employees
Last Reported Date: 03/9/15
Founded in 2006

valeritas inc () Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
President and Chief Commercial Officer
Total Annual Compensation: --
Executive Vice President of Manufacturing, Op...
Total Annual Compensation: --
Vice President of Human Resources
Total Annual Compensation: --
Vice President of Business Development
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

valeritas inc (undefined) Key Developments

Valeritas, Inc. Announces Additional Real World Study Data and Retrospective Analysis

Valeritas Inc. announced additional real world study data and retrospective analyses reported by Diabetes America on Valeritas' lead product, the V-Go Disposable Insulin Delivery Device. The data, collected from electronic records, and the analyses were disclosed in poster presentations at the American Diabetes Association (ADA) 75th Scientific Session in Boston, Massachusetts. The posters presented at ADA complement and strengthen the scientific data and associated analyses recently disclosed in posters at AMCP 2015 and AACE 2015. V-Go is a simple, wearable, basal-bolus insulin delivery solution for patients with diabetes that enables patients to administer a continuous, preset basal rate of insulin over 24 hours and provides on demand bolus dosing at mealtimes with U-100 fast acting insulin. One poster, titled Glycemic Effect with V- Go Based on Baseline Hemoglobin A1C, evaluated the changes that occurred when switching patients with diabetes to V-Go. Data was collected from 151 patients, with an average age of 52 years and known duration of diabetes of 14 years. Patients were stratified by baseline A1Cs into three groups. The results showed that switching patients to V-Go provided a simple way to deliver basal bolus insulin therapy and resulted in significant A1C reductions on less insulin, across the board, regardless of baseline A1C, with the improvements of more than a 3% decrease in patients with A1C's. Another poster, titled Improved Glycemic Control and Reduced Insulin Requirements Over Time with V-Go in Patients with Diabetes, documented a retrospective analysis evaluating the change in glycemic control and insulin dosing for patients unable to achieve glycemic control using other therapies. Information was collected on 72 patients with an average age of 53 years, all who were switched to V-Go and had a minimum of three follow-up A1C values. Results showed, that for 9 months, significant A1C results were maintained while using up to 40% less insulin from baseline.

Valeritas, Inc. Auditor Raises 'Going Concern' Doubt

Valeritas, Inc. filed its S-1/A on Feb 24, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Valeritas, Inc. Presents at Citigroup 2014 Global Healthcare Conference, Feb-24-2014 01:50 PM

Valeritas, Inc. Presents at Citigroup 2014 Global Healthcare Conference, Feb-24-2014 01:50 PM. Venue: Hilton New York, 1335 Avenue of the Americas (Between West 53rd - West 54th Streets), New York, NY 10019, United States. Speakers: Kristine Peterson, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLRX:US $0.00 USD 0.00

Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for undefined.
View Industry Companies
 

Industry Analysis

Industry Average

Valuation Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALERITAS INC, please visit www.valeritas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.